ParenteralDosed ingredient Cosmetic cross-reference

Ammonium Chloride

CAS 12125-02-9

Ammonium Chloride (CAS 12125-02-9) is a Phase 4 pharmaceutical compound with 0 bioactivity targets and 778 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
778
SOURCE IUPHAR/BPS
PubMed IDs
1
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Ammonium Chloride
CAS Number
12125-02-9
UNII
01Q9PC255D
InChIKey
NLXLAEXVIDQMFP-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1200939
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
dosed ingredientparenteral
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1200939 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE DrugCentral 27 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Appendicolith 39 177.624 10074458
Blood phosphorus increased 39 167.966 10050196
Appendicitis 39 138.693 10003011
Ventricular fibrillation 39 123.678 10047290
Cardiogenic shock 39 114.307 10007625
Blood uric acid increased 30 111.18 10005861
Stress 43 97.506 10042209
Myasthenia gravis 25 94.806 10028417
Ascites 41 93.971 10003445
Analgesic therapy 16 91.59 10053469
Sleep disorder therapy 16 91.26 10040990
Drug therapy 16 88.672 10063370
Dry mouth 39 79.932 10013781
Multiple organ dysfunction syndrome 40 75.652 10077361
Abdominal distension 40 72.907 10000060
Hyponatraemia 41 64.328 10021036
Blood cholesterol increased 32 57.479 10005425
Hyperphosphataemia 15 57.065 10020711
Iron deficiency 17 55.875 10022970
Bacterial infection 22 54.019 10060945
Neuralgia 22 53.38 10029223
Hypophosphataemia 18 50.33 10021058
Sepsis 43 49.031 10040047
Somnolence 41 48.902 10041349
General physical health deterioration 42 47.347 10049438
Constipation 43 45.469 10010774
Incorrect route of product administration 20 44.635 10081202

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 1 interaction

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

TargetAction AffinityPubMed
TRPA1
Trpa1
 Activation 2.0 pEC50 19033673
SOURCE NLM RxNorm 2 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
AMMONIUM CHLORIDE 712 SU MTHSPL
ammonium chloride 712 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Ammonium Chloride used for in pharmaceutical contexts?

Ammonium Chloride (CAS 12125-02-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Ammonium Chloride?

Ammonium Chloride has 778 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Appendicolith, Blood phosphorus increased, Appendicitis, Ventricular fibrillation, Cardiogenic shock. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Ammonium Chloride also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Ammonium Chloride with EU status "permitted".

What clinical phase is Ammonium Chloride in?

Ammonium Chloride is rendered with ChEMBL max phase 4 (approved).